Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas

Lymphoma Clinical Trial

Official title:

A Phase I, Dose-Escalation Study to Assess the Safety and Pharmacokinetics of SB- 485232 Administered as Five Daily Intravenous Infusions Repeated Every 28 Days in Adult Patients With Solid Tumors and Lymphomas

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00085904
• Other study ID #: 485232/003
• Secondary ID: 003
• Status: Completed
• Phase: Phase 1
• First received: June 16, 2004
• Last updated: October 9, 2008
• Start date: April 2004

Study information

• Verified date: October 2008
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

SB-485232 will be administered as five daily intravenous (IV) infusions repeated every 28 days in adult subjects with advanced solid tumors or lymphomas. Subjects may receive up to 6 cycles of treatment unless progressive disease or unacceptable toxicity is noted. Three dose levels of drug will be investigated. Safety evaluations, including blood sampling for various laboratory tests, will be conducted. Additional blood samples will also be taken to measure the amount of drug in the body at specific times.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Histopathological confirmation of cancer limited to a solid tumor malignancy or follicular lymphoma.

• Advanced or metastatic disease.

• Measurable disease.

• Females of child-bearing potential must use adequate birth control.

• Karnofsky Performance Status of 70% or greater.

• Predicted life expectancy of at least 12 weeks in the estimation of the physician conducting the study (Principal Investigator).

• Adequate laboratory results.

• Subjects with history of coronary artery disease must have a stress test without clinically significant abnormalities.

• Subjects with a history of congestive heart failure, myocardial infarction or prior anthracycline chemotherapy, must have a MUGA (Multiple Gated Acquisition) scan which demonstrates a left ventricular ejection fraction equal to or greater than 40%.

• Signed informed consent form

Exclusion Criteria:

• Female subject is pregnant or nursing (lactating).

• Active, chronic or uncontrolled infections requiring systemic antibiotic therapy.

• Serious medical or psychiatric disorder that would interfere with the subject''s safety or ability to sign the informed consent.

• Leptomeningeal disease or evidence of prior or current metastatic brain disease.

• Receiving concurrent chemotherapy, immunotherapy, radiotherapy, corticosteroid therapy, or investigational therapy.

• Received chemotherapy, radiotherapy, immunotherapy, hormonal therapy or biological therapy for cancer or underwent a surgical procedure (except for minor surgical procedures) within 4 weeks before beginning treatment with SB-485232 (6 weeks in case of nitrosureas or mitomycin C).

• Exposed to an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of SB-485232.

• Severe concurrent disease or condition, including clinically significant autoimmune disease, which in the judgement of the physician conducting the study (the principal investigator) would render the patient inappropriate for study participation.

• History of ventricular arrhythmias requiring drug or device therapy.

• An unresolved or unstable, serious toxicity from prior administration of another investigational product.

• Psychological, familial, sociological, or geographical limitations that do not permit compliance with this protocol.

• Received prior SB-485232 therapy.

• Poor venous access.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lymphoma
• Solid Tumor Cancer

Intervention

Drug:
• SB-485232

Locations

Country	Name	City	State
United States	GSK Investigational Site	Boston	Massachusetts
United States	GSK Investigational Site	Indianapolis	Indiana
United States	GSK Investigational Site	Pittsburgh	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of adverse events and changes in laboratory values. The potential dose is a dose regimen with no more than 2 out of 6 patients experiencing a dose-limiting toxicity.		6 Months
Secondary	Evaluation for the presence of anti-SB-485232 antibodies, IL-18 neutralizing activity, and clinical sequelae. Pharmacokinetic endpoints are AUC, Cmax, Cmin, CL,Vss, and t1/2. Flow cytometry data. Assessments of disease.		6 Months